SAN DIEGO, CA August 21, 2008/MarketWire/– Aegis Therapeutics, a drug delivery technology licensing company and leader in transmucosal drug delivery, will present a talk entitled: “New Technologies Expanding Practical Clinical Uses of Peptides, Proteins, and Other Macromolecular Therapeutics” at Insight’s “13th Annual Drug Delivery Summit”. The conference will be held on September 22-23, 2008 at the Hyatt Regency, New Brunswick, NJ. Dr. Edward T. Maggio, President and CEO of Aegis, will present studies on the application of Aegis’ Intravail® non-invasive drug delivery technology, and Aegis’ ProTek® protein stabilization technology to specific peptide, protein, and small molecule therapeutics.
Information about the conference may be obtained from the following website: http://www.insightinfo.com/index.cfm?ci_id=25551&la_id=1.
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis’ Intravail® absorption enhancement agents provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal administration route. Intravail® has also been successfully applied to buccal, oral, and rectal administration of both small molecule and peptidic drugs. Our ProTek® technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek® technology is applicable to injectable, intranasal, and other dosage forms of peptide or protein therapeutics.
For more information about Aegis, please visit the Aegis website at: htpp://www.aegisthera.com.